He better have found something to say with regard to his part in critical examinination of this trial data and normal limitations of trial designs and comparators which are never perfect. He was hired to be impartial with the knowledge that his protocol and part in the Optune device from NVCR were being challenged so this should come as no surprise. Now we also know that the L Phase 3 data surprised with regard to rGBM patients that did not have a second resection living longer compared to those who did. What did he have to say about that and how other unexpected groups of patients like the elderly and those with low absolute lymphocyte count were seeing benefit as well?; ). Well maybe just the possible overseeing of the use of matched comparators was what was most important; ). I mean who better right?; ). Best wishes.
Market Data 
Markets 
AI
